Wanxin Li

Wanxin Li

Auto-generated profile, based on publicly available information

Wanxin Li

School of Public Health, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in NEJM AI
Verified
Journal Article
Closed access
JWJiageng Wu
Jiageng Wu
XLXiaocong Liu
Xiaocong Liu
MLMinghui Li
Minghui Li
WLWanxin Li
Wanxin Li
ZSZichang Su
Zichang Su
JYJie Yang
Jie Yang

5 March 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
WLWanxin Li
Wanxin Li
YHYining Hua
Yining Hua
PZPeilin Zhou
Peilin Zhou
LZLi Zhou
Li Zhou
XXXin Xu
Xin Xu
JYJie Yang
Jie Yang
Background: While the COVID-19 pandemic has induced massive discussion of available medications on social media, traditional studies focused only on limited aspects, such as public opinions, and endured reporting biases, inefficiency, and long collection times. Objective: Harnessing drug-related data posted on social media in real-time can offer insights into how the pandemic impacts drug use and monitor misinformation. This study aimed to develop a natural language processing (NLP) pipeline tailored for the analysis of social media discourse on COVID-19–related drugs. Methods: This study constructed a full pipeline for COVID-19–related drug tweet analysis, using pretrained language model–based NLP techniques as the backbone. This pipeline is architecturally composed of 4 core modules: named entity recognition and normalization to identify medical entities from relevant tweets and standardize them to uniform medication names for time trend analysis, target sentiment analysis to reveal sentiment polarities associated with the entities, topic modeling to understand underlying themes discussed by the population, and drug network analysis to dig potential adverse drug reactions (ADR) and drug-drug interactions (DDI). The pipeline was deployed to analyze tweets related to the COVID-19 pandemic and drug therapies between February 1, 2020, and April 30, 2022. Results: From a dataset comprising 169,659,956 COVID-19–related tweets from 103,682,686 users, our named entity recognition model identified 2,124,757 relevant tweets sourced from 1,800,372 unique users, and the top 5 most-discussed drugs: ivermectin, hydroxychloroquine, remdesivir, zinc, and vitamin D. Time trend analysis revealed that the public focused mostly on repurposed drugs (ie, hydroxychloroquine and ivermectin), and least on remdesivir, the only officially approved drug among the 5. Sentiment analysis of the top 5 most-discussed drugs revealed that public perception was predominantly shaped by celebrity endorsements, media hot spots, and governmental directives rather than empirical evidence of drug efficacy. Topic analysis obtained 15 general topics of overall drug-related tweets, with “clinical treatment effects of drugs” and “physical symptoms” emerging as the most frequently discussed topics. Co-occurrence matrices and complex network analysis further identified emerging patterns of DDI and ADR that could be critical for public health surveillance like better safeguarding public safety in medicines use. Conclusions: This study shows that an NLP-based pipeline can be a robust tool for large-scale public health monitoring and can offer valuable supplementary data for traditional epidemiological studies concerning DDI and ADR. The framework presented here aspires to serve as a cornerstone for future social media–based public health analytics.

3 April 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
WLWanxin Li
Wanxin Li
XZXuan Zhou
Xuan Zhou
SYShuai Yuan
Shuai Yuan
LWLijuan Wang
Lijuan Wang
LYLili Yu
Lili Yu
XLXue Li
Xue Li
Background: Human gut microbiome has complex relationships with the host, contributing to metabolism, immunity, and carcinogenesis. Methods: Summary-level data for gut microbiota and metabolites were obtained from MiBioGen, FINRISK and human metabolome consortia. Summary-level data for colorectal cancer were derived from a genome-wide association study meta-analysis. In forward Mendelian randomization (MR), we employed genetic instrumental variables (IV) for 24 gut microbiota taxa and six bacterial metabolites to examine their causal relationship with colorectal cancer. We also used a lenient threshold for nine apriori gut microbiota taxa as secondary analyses. In reverse MR, we explored association between genetic liability to colorectal neoplasia and abundance of microbiota studied above using 95, 19, and 7 IVs for colorectal cancer, adenoma, and polyps, respectively. Results: Forward MR did not find evidence indicating causal relationship between any of the gut microbiota taxa or six bacterial metabolites tested and colorectal cancer risk. However, reverse MR supported genetic liability to colorectal adenomas was causally related with increased abundance of two taxa: Gammaproteobacteria (β = 0.027, which represents a 0.027 increase in log-transformed relative abundance values of Gammaproteobacteria for per one-unit increase in log OR of adenoma risk; P = 7.06×10−8), Enterobacteriaceae (β = 0.023, P = 1.29×10−5). Conclusions: We find genetic liability to colorectal neoplasia may be associated with abundance of certain microbiota taxa. It is more likely that subset of colorectal cancer genetic liability variants changes gut biology by influencing both gut microbiota and colorectal cancer risk. Impact: This study highlights the need of future complementary studies to explore causal mechanisms linking both host genetic variation with gut microbiome and colorectal cancer susceptibility.

18 January 2025 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
SLShixu Lin
Shixu Lin
LGLucas Garay
Lucas Garay
YHYining Hua
Yining Hua
ZGZhijiang Guo
Zhijiang Guo
WLWanxin Li
Wanxin Li
JYJie Yang
Jie Yang


16 September 2024
Verified
Other
Open access
WLWanxin Li
Wanxin Li
XZXuan Zhou
Xuan Zhou
SYShuai Yuan
Shuai Yuan
LWLijuan Wang
Lijuan Wang
LYLili Yu
Lili Yu
XLXue Li
Xue Li
Supplementary Methods shows the formulas for calculating F-statistics.